News

Sofinnova Partners raises €1.2 billion to fuel the next wave of life sciences innovation

Leading European venture capital firm exceeds €4 billion in…

Novo Holdings and TA Associates partner with Biocomposites to drive next chapter of its growth

Additional investment and resources will accelerate Biocomposites’…

Domain Therapeutics to present and participate at major global healthcare conferences, March to June 2025

Domain’s leadership will highlight advancements in its key…

Experienced Industry Leader Tom Arnold Appointed as Chief Executive Officer of ViCentra

Experienced MedTech leader to scale manufacturing, drive…

Ottimo Pharma Strengthens Leadership Team with Senior Appointments

Robert Tighe appointed as Senior Vice President of Preclinical…

LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors

Dr Mozayeni brings deep experience in biotech corporate strategy…

U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy

225Ac-satoreotide is a first-in-class Actinium-labelled somatostatin…

Liva Healthcare acquires Momenta, and secures funding from new and existing investors to drive growth

Purchase of UK-based Discover Momenta and Momenta Newcastle…

Akribion Therapeutics exits from stealth with €8m seed financing to pioneer RNA-guided, programmable cell depletion

Financing led by CARMA FUND and RV Invest with participation…

Alys Pharmaceuticals receives IND clearance for Phase 2a trial of first genetic medicine program in dermatology

ALY-101 is an intradermal injectable JAK1 siRNA-lipid conjugate…

Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year

In 2024, on its 100th anniversary, the Novo Nordisk Foundation…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.